Triapine (3-AP)

目录号：S7470 Purity: 99.92%

Triapine (3-AP) 是一种强效的ribonucleotide reductase (RNR)抑制剂，通过抑制DNA的合成而具有广谱抗肿瘤活性。

Triapine (3-AP) Chemical Structure

CAS: 200933-27-3

规格	价格	库存
10mM (1mL in DMSO)	RMB 997	现货
10mg	RMB 811.33	现货
25mg	RMB 1933.42	现货
100mg	RMB 5561.01	现货
1g	RMB 24488.1	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

客户使用Selleck的Triapine (3-AP)发表文献16篇

客户使用该产品的1个实验数据

产品质控

批次：纯度： 99.92%

99.92

Triapine (3-AP)相关产品

相关靶点	tRNA synthetase RdRp DNA synthesis helicase ribonucleotide reductase	点击展开
相关化合物库	FDA药物库天然产物库凋亡分子化合物库 DNA损伤/ DNA修复化合物库细胞周期化合物库	点击展开

DNA/RNA Synthesis抑制剂选择性比较

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
HCT116	Function assay	4 uM	24 hrs	Induction of ROS generation in human HCT116 cells expressing wild type p53 at 4 uM after 24 hrs by spectrophotometry	24900837
SW480	Function assay	2.5 uM	48 hrs	Induction of morphological changes in human SW480 cells assessed as induction of massive cell flattening at 2.5 uM incubated for 48 hrs by phase contrast microscopy	27336684
HL60	Function assay	1 and 5 uM	30 mins	Induction of intracellular ROS generation in human HL60 cells at 1 and 5 uM in presence of CuCl2 incubated for 30 mins by DCF-DA staining based fluorescence assay	27336684
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50=0.26μM	17602603
KB-3-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay, IC50=1.4μM	19397322
KB-3-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay, IC50=1.41254μM	19397322
KBV1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay, IC50=5.88844μM	19397322
KBV1	Cytotoxicity assay		72 hrs	Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay, IC50=5.9μM	19397322
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50=0.26μM	19601577
HCT116	Dark cytotoxicity assay		96 hrs	Dark cytotoxicity against human HCT116 cells expressing wild type p53 after 96 hrs by MTT assay, IC50=1.226μM	24900837
HCT116	Photocytotoxicity assay		24 hrs	Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3	24900837
KB-3-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay, IC50=3.1μM	27336684
KBC1	Cytotoxicity assay		72 hrs	Cytotoxicity against human KBC1 cells incubated for 72 hrs by MTT assay, IC50=8.9μM	27336684
WPMY-1	Antiproliferative assay		72 hrs	Antiproliferative activity against human WPMY-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay, IC50=4.96μM	31614257
GES-1	Antiproliferative assay		72 hrs	Antiproliferative activity against human GES-1 cells assessed as reduction in cell proliferation incubated for 72 hrs by MTT assay, IC50=5.6μM	31614257
GES-1	Cytotoxicity assay		72 hrs	Cytotoxicity against human GES-1 cells after 72 hrs by MTT assay, IC50=5.4μM	ChEMBL
MGC803	Antiproliferative assay		72 hrs	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay, IC50=9.68μM	ChEMBL
MCF7	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=18.85μM	ChEMBL
SMMC7721	Antiproliferative assay		72 hrs	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay, IC50=42.81μM	ChEMBL
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	18159922
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50=0.54μM	17963372
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50=0.31μM	17142046
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	27336684
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	27336684
L1210	Growth inhibition assay			Growth inhibition of mouse L1210 cells by MTS assay, IC50=1.3μM	30904782
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	31614257
HEK293	Cytotoxicity assay			Cytotoxicity against HEK293 cells (CO-ADD:MA_007); CC50 by cell viability assay in DMEM (10% FBS) media using TC plates, by Resazurin F(560/590), CC50=2.827μM	ChEMBL
点击查看更多细胞系数据

生物活性

产品描述

Triapine (3-AP) 是一种强效的ribonucleotide reductase (RNR)抑制剂，通过抑制DNA的合成而具有广谱抗肿瘤活性。

靶点

Ribonucleotide reductase ^[1]

体外研究(In Vitro)
体外研究活性	在野生型KB和HU-抗性KB的鼻咽癌细胞中，Triapine抑制核苷酸还原酶的活性。在一系列的肿瘤细胞系中，Triapine通过抑制DNA合成具有广谱的抗肿瘤活性。^[1]在体外实验中，Triapine阻断缺血性的神经毒性和低氧毒性，其EC50分别是0.35 μM 和 0.75 μM。Triapine通过抑制神经毒剂，包括星状孢菌素，藜芦定和谷氨酸等诱导的细胞死亡，表现出神经保护活性。^[2]
激酶实验	核糖核苷酸还原酶实验
激酶实验	CDP还原酶通过Dowex 1-borate离子交换色谱测定。实验体系包含0.02 μCi [¹⁴C]CDP (52.9 mCi/mmol), 3 mM 二硫苏糖醇，6 mM MgCl₂，30 mM HEPES，5 mM ATP，0.15 mM 未标记的CDP，以及10 μL 细胞提取物，终体积为0.02 毫升。反应的培养时间为60分钟，反应和时间呈线性关系。
细胞实验	细胞系	野生型KB和HU抵性KB鼻咽癌
	浓度	~10 μM
	孵育时间	第3代时期
	方法	细胞以10⁴每孔的密度接种于24孔板上，药物加入到细胞中，连续培养3代（未经处理的对照细胞），随后用亚甲基蓝试验测定细胞生长。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	p-Chk1 / Chk1 / p-CDK1/2 / CDK1/2 / p-H1		24413181
	Growth inhibition assay	Cell viability		31118677

体内研究(In Vivo)
体内研究活性	在有L1210白血病的小鼠中，Triapine (1.25~20 毫克/千克)能够治疗一些小鼠且没有致命毒性。Triapine同时抑制小鼠M109 肺癌和人 A2780 卵巢癌的肿瘤生长。此外，联合使用Triapine和其它的损伤DNA的抑制剂能够对L1210 白血病协同抑制。^[1]在大鼠瞬时缺血模型中，当(50 μ 每只大鼠)注射时，Triapine 减少59%的梗死体积，静脉注射(1 毫克/千克)时，减少35%的梗死体积。^[2]
动物实验	Animal Models	患有L1210白血病和 M109肺肿瘤的BALB/cBA/2 (CD2F1)小鼠，异种移植人A2780卵巢癌的无胸腺nu/nu小鼠。
	Dosages	~24毫克/千克
	Administration	腹腔注射或静脉注射

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT00293345	Completed	Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia/Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides/Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides/Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	June 2006	Phase 1

参考文献
[1] Finch RA, et al. Biochem Pharmacol. 2000, 59(8), 983-991. [2] Jiang ZG, et al. CNS Drug Rev. 2006, 12(1), 77-90.

参考文献

化学信息&溶解度

分子量	195.24	分子式	C₇H₉N₅S
CAS号	200933-27-3	SDF	Download Triapine (3-AP) SDF
Smiles	C1=CC(=C(N=C1)C=NNC(=S)N)N
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 39 mg/mL ( (199.75 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

* 姓名 请输入您的姓名

* 邮箱 请输入您的邮箱地址 请输入一个有效的邮箱地址

电话

* 留言内容 请写点东西给我们

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):